Keyphrases
PET Imaging
100%
Dosimetry
100%
Safety Assessment
100%
P(LLA-CL)
100%
First-in-human
100%
Human Evaluation
100%
Multiple Myeloma
27%
VLA-4
27%
Radiation Dosimetry
18%
Radiopharmaceuticals
18%
Effective Dose
18%
Time-activity Curve
18%
Cell-based
9%
Adverse Events
9%
Kidney
9%
Safety Profile
9%
Pharmacokinetics
9%
Bladder
9%
High Affinity
9%
Positron Emission Tomography-computed Tomography (PET-CT)
9%
Biodistribution
9%
Flow Cytometry
9%
MR Scan
9%
Integrin
9%
High-performance Liquid Chromatography
9%
Imaging Data
9%
CD-1 Mice
9%
PET-MRI
9%
Imaging Dose
9%
Red Marrow
9%
Spleen
9%
Male Mice
9%
Human Serum
9%
Tolerability
9%
Radiotracer
9%
Bioactivity
9%
Imaging Time
9%
Residence Time
9%
Analysis Support
9%
Biopsy Tissue
9%
Human Studies
9%
Toxicity Study
9%
Microenvironment
9%
Binding Assay
9%
Female Mice
9%
Radio
9%
Myeloma Cells
9%
Blood Metabolism
9%
Body Imaging
9%
Differentially Expressed
9%
Cell Studies
9%
Unmet Needs
9%
Metabolism Study
9%
Multiple Myeloma Patients
9%
Healthy Participants
9%
CD-1
9%
Color Flow
9%
NOAEL
9%
Organ Absorbed Dose
9%
Good Manufacturing Practice
9%
Human Participants
9%
Targeted Imaging Agents
9%
Organ Uptake
9%
Early Imaging
9%
Assessment Software
9%
Organ Level
9%
Environmental Cell
9%
Image Quality Analysis
9%
Internal Dose Assessment
9%
Mass Excess
9%
Medicine and Dentistry
Positron Emission Tomography
100%
Dosimetry
100%
Copper 64
100%
Radioactive Tracer
55%
Multiple Myeloma
55%
Adverse Event
22%
Radiopharmaceutical
22%
Positron Emission Tomography-Computed Tomography
11%
Bladder
11%
Imaging Agent
11%
Flow Cytometry
11%
Metabolite
11%
High-Performance Liquid Chromatography
11%
Image Quality
11%
Single Drug Dose
11%
Human Study
11%
Absorbed Dose
11%
Pharmacokinetics
11%
Biodistribution
11%
Biopsy Technique
11%
Binding Assay
11%
Myeloma Cell
11%
Polyethylene Terephthalate
11%
Integrin
11%
Biological Activity
11%
Pharmacology, Toxicology and Pharmaceutical Science
Dosimetry
100%
Copper 64
100%
Polyethylene Terephthalate
100%
Multiple Myeloma
55%
Tracer
55%
Adverse Event
11%
High Performance Liquid Chromatography
11%
CD-1 Mouse
11%
Integrin
11%
Biodistribution
11%
Flow Cytometry
11%
Tolerability
11%
Human Study
11%
Good Manufacturing Practice
11%
No-Observed-Adverse-Effect Level
11%
Pharmacokinetics
11%